Relapsed/Refractory B-NHL is a type of blood cancer that comes back (relapsed) or doesn't respond to treatment (refractory). This study is testing a new drug called SynKIR-310 to see if it's safe and works well for people with this condition. Participants will receive just one dose of the drug through an intravenous (IV) line, which is a tube that puts the medicine directly into the blood. The trial is in its early phase, known as Phase 1, where researchers mainly check for safety and how people react to the treatment.
- Participants must be at least 18 years old and have a confirmed diagnosis of B-NHL.
- The study will have up to 36 participants and involves multiple visits to the research center.
- Participants should not have had any other investigational treatments 30 days before joining the study.
People who have tried other therapies like CAR T-cell therapy but didn't respond or whose disease returned might find this trial suitable. Before joining, participants will be checked to ensure they meet all study rules, including health and treatment history.